Key facts
- This page summarizes Jeffrey L. Wade's Form 4 filing for LEXICON PHARMACEUTICALS, INC. (LXRX).
- 7 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 29 Feb 2024, 16:32.
Jeffrey L. Wade - 28 Feb 2024 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)
- Reporting relationship
- President and CFO
- Issuer ticker
- LXRX
- Reported as of
- 28 Feb 2024
- Net transaction value
- -$98,750
- SEC form
- 4
- Accepted by SEC
- 29 Feb 2024, 16:32:30 UTC
- Prior SEC filing
- 12 Feb 2024
- Next SEC filing
- 08 Jul 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jeffrey L. Wade
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jeffrey L. Wade filed Form 4 for LEXICON PHARMACEUTICALS, INC. (LXRX) on 29 Feb 2024.
Change
- Previous filing in this sequence was filed on 12 Feb 2024.
- Current net transaction value: -$98,750.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LXRX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +11,177
- Change %
- +4.2%
- Price
- Shares after
- 275,518
- Date
- 28 Feb 2024
- Ownership
- Direct
- Footnotes
- F1
LXRX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +37,274
- Change %
- +14%
- Price
- Shares after
- 312,792
- Date
- 28 Feb 2024
- Ownership
- Direct
- Footnotes
- F1
LXRX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +49,113
- Change %
- +16%
- Price
- Shares after
- 361,905
- Date
- 28 Feb 2024
- Ownership
- Direct
- Footnotes
- F1
LXRX
transaction
Common Stock
Tax liability
- Transaction value
- $98,750
- Shares
- -37,691
- Change %
- -10%
- Price
- $2.62
- Shares after
- 324,214
- Date
- 28 Feb 2024
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LXRX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- Shares
- -11,177
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 28 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 11,177
- Exercise price
- Footnotes
- F1, F3
LXRX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- Shares
- -37,274
- Change %
- -50%
- Price
- Shares after
- 37,273
- Date
- 28 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 37,274
- Exercise price
- Footnotes
- F1, F3
LXRX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- Shares
- -49,113
- Change %
- -33%
- Price
- Shares after
- 98,227
- Date
- 28 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 49,113
- Exercise price
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of common stock.
Footnote F2
Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.
Footnote F3
Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.